South Korea’s MFDS retains conditional approval for Neuronata‑R ALS stem‑cell therapy, preserving patient access while the developer readies supply resumption and a U.S. research base
Executive summary: South Korea's Ministry of Food and Drug Safety updated and retained the conditional approval for Neuronata‑R, a stem cell therapy for ALS, in May 2026, with the status confirmed as of July 2026. Continued approval maintains patient access to the therapy in South Korea and signals the developer’s intent to resume supply and build a U.S. research base, which are prerequisites for broader commercialization and potential future approvals elsewhere.
Who is involved: The developer of Neuronata‑R (unspecified in the release) and South Korea’s Ministry of Food and Drug Safety.
Likely next: The developer will resume product supply and establish a U.S. research base to gather additional data needed for expanded regulatory submissions.
The Ministry of Food and Drug Safety in South Korea has decided to keep the conditional approval granted in May 2026 for Neuronata‑R, a stem‑cell‑based treatment for amyotrophic lateral sclerosis. This decision allows the therapy to remain available to patients in the country while the manufacturer works to restart distribution and establishes a research presence in the United States to support future regulatory steps.
Timeline
- — Neuronata-R retains conditional approval in South Korea (PR Newswire)
Analysis — what this means
Likely next events
- Developer to resume supply of Neuronata‑R
- Developer to establish a U.S. research base for Neuronata‑R
Sectors affected
- Biotechnology
- ALS treatment
- Stem cell therapy
Regulatory implications
- Conditional approval requires ongoing submission of efficacy and safety data to South Korea MFDS
Key entities
Sources
- Neuronata-R retains conditional approval in South Korea — PR Newswire